Naphthalene lipoxygenase-inhibiting agents
US5155132A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 21, 1988 |
| Grant date | Oct 13, 1992 |
| Priority date | — |
| Expiry date | Mar 21, 2008 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C50/24
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is lower alkoxy or optionally substituted phenoxy; PA0 R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substituted phenylalkyl; PA0 R.sup.3 is hydrogen, lower alkyl, lower alkoxy, halo, optionally substituted phenyl, optionally substituted phenyl-lower-alkyl or optionally substituted phenyl-lower-alkoxy, and m is 1 or 2; PA0 X and Y are different and are either R.sup.4 or --C(O)W wherein PA0 R.sup.4 is lower alkyl or optionally substituted phenyl-lower-alkyl; PA0 W is --OR.sup.5 or --NR.sup.6 R.sup.7, wherein PA0 R.sup.5 is alkyl, optionally substituted phenyl or optionally substituted benzyl; and R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl, cycloalkyl or optionally substituted phenyl. The compounds of this invention are also useful for the treatment of disease-states caused by lipoxygenase activity in mammals, particularly 5-lipoxygenase activity, when administered systemically.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.